Stay updated on Pembrolizumab Effects in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Effects in Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab Effects in Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe site revision was updated to v3.6.6, indicating a platform-level update. This change does not alter the study content or user-facing details on the NCT02644369 page.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedA broad set of disease-related MeSH terms and categories were added to the study record, expanding the indexed topics (e.g., Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms, etc.). This broadens how the study can be found and linked to related conditions and terminologies.SummaryDifference50%

- Check38 days agoChange DetectedA new revision label, Revision: v3.6.5, was added and the previous Revision: v3.6.4 was removed, indicating a small update to the page’s revision history.SummaryDifference0.1%

- Check52 days agoChange DetectedA new Revision line appears: Revision: v3.6.4, replacing the previous v3.6.3, indicating an update to the page's version.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.6.3 was added to replace Revision: v3.6.2, reflecting a newer release tag for the page. This appears to be a metadata/version update and does not modify the study details or visible content.SummaryDifference0.1%

- Check80 days agoChange DetectedRevision: v3.6.2 is now shown on the page, replacing the previous v3.6.0. This reflects an internal update to the site’s versioning or CMS rather than a change to the study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Effects in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Effects in Solid Tumors Clinical Trial page.